Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Traders added an estimated $54.6 million to the Direxion Daily S&P Biotech Bull 3X ETF (NYSEARCA:LABU). That works out to 9.10% of the fund’s assets, according to ETF flow data from October 14, 2026. Measured against fund size, it was the largest inflow in the entire dataset.
The unleveraged State Street SPDR S&P Biotech ETF (NYSEARCA:XBI) pulled in more money, an estimated $304.3 million. Against its $10.01 billion asset base, though, that came to only 3.00%. LABU holds $597.1 million, so a flow of that size changes who owns the fund. That makes the inflow worth a closer look before anyone takes it as a vote of confidence.
What LABU Actually Is and How the Daily Reset Works
LABU is a Direxion fund that aims to deliver triple the daily move of the S&P Biotech Select Industry Index, the same index XBI tracks without leverage. Its July 31 portfolio filing lists 112 positions. Alongside the biotech stocks sit large money-market balances and derivative contracts, which are how the fund gets its extra exposure.
Tripled daily exposure to small and midsize drug developers is among the most volatile options available in a listed fund. The key word in the name is “Daily.” At the end of each session, the fund rebalances so it starts the next day at three times its assets in index exposure. Like all leveraged ETFs, it is meant for brief use. Hold it for weeks or months and your return can drift far from three times what the index did.
That drift is called volatility decay: a fund that resets every day loses ground when gains and losses alternate. Picture the index at $100. It rises 10% one day and falls 10% the next, ending at $99. A 3x fund on the same path gains 30%, then loses 30%, and ends at $91. The index finished near breakeven while the leveraged fund took a far larger loss. The more the market chops back and forth, the more ground the fund gives up.
Why Tripling Biotech Compounds the Problem
Biotech already swings hard without leverage. Clinical trial readouts, FDA decisions and interest-rate expectations all move the sector, since many developers burn cash and depend on capital markets for funding. A rebound in 2026 has been driven by big acquisitions and a busy IPO market, BioPharma Dive reported in August 2026.
LABU’s numbers show what leverage does to that path. Over one year through Thursday afternoon, XBI gained 42.76%. Three times that move would be 128.28%. LABU actually returned 107.58%.
| Period (through Oct. 15, 2026) | LABU | XBI |
|---|---|---|
| One month | -17.4% | -5.17% |
| Year to date | 39.08% | 22.69% |
| One year | 107.58% | 42.76% |
| Five years | -79.14% | 20.23% |
The year-to-date gap shows the same thing. Tripling XBI’s gain would give 68.07%, well above what LABU delivered.
Over five years, the gap widened sharply. Someone who put $10,000 into XBI on October 15, 2021 would have about $12,023 today. That $10,000 in LABU would be worth roughly $2,086. The index ended that period higher, while the leveraged fund lost most of its value along the way.
What the Inflow Tells Investors and What It Leaves Out
The flow figure is an total estimate across all buyers and sellers. What it does show is demand for greater biotech exposure after a sharp pullback: LABU sits 17.4% below its September 14 price. On Thursday, LABU was up 5.55% by mid-afternoon, while XBI rose 1.83%.
The flow data leaves key questions open. The flow data does not say what period it covers. It also cannot show how long the new money plans to stay. Leveraged fund assets tend to turn over quickly, and shares created during a dip can be redeemed just as fast. A large inflow into a 3x product mostly shows that traders want short-term exposure. It says much less about long-term conviction in biotech.
Who This Product Is Built For
LABU exists for active traders who check their positions every session and want greater one-day exposure to biotech catalysts, such as a rate decision or a group of trial readouts. Its appeal is real: tripled exposure without a margin account, and losses limited at the amount invested. Its daily reset makes it a tool for brief holding periods, and the discipline it requires (small size, strict rules) is the same framework we laid out in a free guide to speculating with a sliver of a portfolio.
Next, watch whether the next round of flow data shows this money staying put or leaving. Also watch whether XBI can win back the 5.17% it has lost over the past month. If biotech continues chopping sideways, decay will continues eating into LABU even if the index goes nowhere.
Contact [email protected] for any questions or corrections.
Jake has been been working in financial media for almost 15 years. He focuses on all things personal finance for 24/7 Wall St. with high hopes to educate and entertain. Most recently, Jake spent 12 years working various roles at The Motley Fool. He started copy editing fool.com content, worked on premium and marketing campaigns, and helped launch The Ascent, a personal finance brand.
His work has been featured on platforms like MSN, Yahoo Finance, USA Today, and more. He's written about credit cards, social security, ETFs, savings accounts, and just about anything else you can imagine when thinking about money. Jake love to cook, play golf, and tell people he's never had a cavity. (It's true!)
